Hormonal
Hormone replacement therapy (HRT) with estrogen plus progestin in postmenopausal women increases the risk of coronary heart disease, stroke, and pulmonary embolism without improving cardiovascular outcomes.
If you are a postmenopausal woman considering hormone replacement therapy, understand that current evidence suggests it does not prevent heart disease and may actually increase the risk of heart attacks, strokes, and blood clots. It should only be used to manage severe menopausal symptoms for the shortest duration possible, after a thorough discussion of risks with your doctor.
The combined oestrogen and progestin component of the WHI was stopped early, as women taking hormonal therapy were determined to have an excessive risk of breast cancer... risks of coronary heart disease, stroke and pulmonary embolism were significantly increased in the oestrogen + progestin group.
Why this rating
Based on the Women's Health Initiative, a major randomized, double-blind, placebo-controlled clinical trial.
Source
The endocrine system and ageing
HS Chahal et al. · The Journal of Pathology · 2007
DOI 10.1002/path.2110
More from this paper
- Testosterone supplementation in older men with low testosterone levels does not consistently improve muscle strength or functional ability, despite increasing lean body mass and decreasing fat mass.Good
- DHEA supplementation in healthy older adults does not improve well-being, cognition, or sexual function, and its decline with age does not necessarily cause these impairments.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →